Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CBC-Derived Biomarkers Associated With Recurrence After Sinus Surgery in Chronic Rhinosinusitis.

The Laryngoscope·2026
Same author

Development of a longitudinal predictive model for hepatocellular carcinoma occurrence in patients with chronic hepatitis B.

Scientific reports·2026
Same author

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 as a Biomarker for Predicting Response to Erlotinib and Gefitinib in Lung Adenocarcinoma: An Integrative Analysis of Transcriptomic Data of PC-9 and Drug-Resistant PC-9 Cell Lines.

International journal of molecular sciences·2026
Same author

The Effect of Viniferin on Liver Cancer: Research Based on Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation.

Medical sciences (Basel, Switzerland)·2026
Same author

Trends in skin cancer incidence in Songkhla, Southern Thailand, 1989-2020: A population-based study on the impact of geographic variation.

PloS one·2026
Same author

A Patient-Derived Organoid Platform from TUR-P Samples Enables Precision Drug Screening in Advanced Prostate Cancer.

Cancers·2025

Related Experiment Video

Updated: Jun 4, 2025

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

900

Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a

Pritsana Raungrut1, Suchanan Tanyapattrapong1, Thipphanet Masjon1

  • 1Division of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkhla University, Hat Yai 90110, Songkhla, Thailand.

Current Issues in Molecular Biology
|December 27, 2024
PubMed
Summary

Researchers developed drug-resistant lung cancer cells to find new treatment targets. Colony-stimulating factor 3 (CSF3) was identified as a key biomarker for chemotherapy response in adenocarcinoma patients.

Keywords:
biomarkerscarboplatinchemoresistancenon-small cell lung cancerpaclitaxeltranscriptomic profiling

More Related Videos

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

8.7K
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

9.9K

Related Experiment Videos

Last Updated: Jun 4, 2025

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

900
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

8.7K
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

9.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Lung adenocarcinoma is a significant cause of cancer mortality.
  • Acquired resistance to chemotherapy, including carboplatin (Car) and paclitaxel (Pac), remains a major clinical challenge.
  • Identifying molecular mechanisms underlying drug resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To generate carboplatin- and paclitaxel-resistant human lung adenocarcinoma cell lines (H1792/Car and H1792/Pac).
  • To perform transcriptome sequencing to identify common differentially expressed genes (Co-DEGs) and hub genes associated with drug resistance.
  • To validate potential biomarkers for predicting treatment response in lung adenocarcinoma.

Main Methods:

  • Generation of drug-resistant cell lines through prolonged drug exposure.
  • Transcriptome sequencing (RNA-Seq) to analyze gene expression profiles.
  • Bioinformatic analysis to identify Co-DEGs and hub genes.
  • Online databases (GEPIA, Kaplan-Meier Plotter) and experimental validation (RT-qPCR) for gene expression and survival analysis.

Main Results:

  • H1792/Car and H1792/Pac cell lines showed significantly increased resistance to carboplatin (10.7-fold) and paclitaxel (5.6-fold).
  • Transcriptomic analysis revealed 123 Co-DEGs (72 upregulated, 51 downregulated) and 13 hub genes.
  • Colony-stimulating factor 3 (CSF3) was identified as a key hub gene, significantly upregulated in resistant cells and associated with post-progression survival (PPS) in lung adenocarcinoma patients.

Conclusions:

  • Drug-resistant cell line models are valuable for discovering biomarkers of therapeutic resistance.
  • CSF3 is a potential predictive biomarker for carboplatin- and paclitaxel-based chemotherapy in lung adenocarcinoma.
  • CSF3 may serve as a molecular target for overcoming or optimizing chemotherapy regimens.